United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - perindopril erbumine - oral tablet - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - perindopril erbumine - oral tablet - 2mg

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc - perindopril erbumine (unii: 1964x464oj) (perindopril - unii:y5gmk36kgy) - perindopril erbumine 2 mg - stable coronary artery disease perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. when using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (see warnings .) in considering use of

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; silica dimethyl silylate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; lactose monohydrate; microcrystalline cellulose; magnesium stearate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; magnesium stearate; microcrystalline cellulose; lactose monohydrate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - perindopril erbumine - oral tablet - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - perindopril erbumine - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - perindopril erbumine - oral tablet - 8mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - perindopril erbumine - oral tablet - 2mg